SMAD7 antisense oligonucleotides and sphingosine‐1‐phosphate receptor modulators are new oral agents that are being investigated as potential treatments for inflammatory bowel disease (Crohn's disease and ulcerative colitis). This article reports… Click to show full abstract
SMAD7 antisense oligonucleotides and sphingosine‐1‐phosphate receptor modulators are new oral agents that are being investigated as potential treatments for inflammatory bowel disease (Crohn's disease and ulcerative colitis). This article reports on some of the clinical trial outcomes so far.
               
Click one of the above tabs to view related content.